555 Background: Stratipath Breast is an AI-based prognostic medical device for risk stratification of early-stage breast cancer using routine H DRFI HR = 1.61, 95%CI: 1.30-1.99, p < 0.05). Stratipath risk category remained significant in multivariable analysis when histologic grade was included, whereas grade did not. RS remained prognostic significant in multivariable analyses together with Stratipath Breast, indicating potentially complementary prognostic information. C-index improved with inclusion of Stratipath Breast together with clinical variables and RS, exceeding that of grade. Conclusions: In the TAILORx trial Stratipath Breast was found to provide significant prognostic value. Stratipath Breast also provided independent prognostic value in multivariable analysis adjusting for standard clinicopathologic factors and RS. These findings support the clinical relevance of AI-driven morphology-based biomarkers for breast cancer risk stratification.
Hartman et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: